14th Annual Immunogenicity Bioassay Summit

October 3-6, 2022 | USA

14th Annual
CHI is excited to host its 14th Annual Immunogenicity & Bioassay Summit at the Crystal Gateway Marriott in Washington, D.C. We’ll examine challenges facing the industry with NEW case studies, NEW perspectives and NEW approaches. Learn from industry, academia and the FDA at 3 Conference Programs,

Spotlight

Mesenchymal stromal cells (MSCs) are prime candidates for regenerative medicine and therapeutic applications due to both their potent immuno-modulatory function and a unique ability to proliferate and differentiate into a variety of cell lineages. However, the stresses incurred during bio preservation /stability intervals (non-frozen and cryopreserved), including transit to and from the clinic can render MSCs ineffective and potentially unsafe. Challenges related to the formulation, transportation, distribution and delivery of source material (tissue, blood, marrow) and MSC-based products are important and inter-related components of the supply chain and scale-up. Effective bio preservation can optimize the quality of cell/tissue source material and final cell/tissue products, mitigate the adverse effects of interruptions and unforeseen events throughout the supply chain, as well as support the return to function of MSCs following patient administration.


OTHER PAST CONFERENCES

International Conference on Probiotics and Prebiotics

June 15-16, 2022 | Italy

Magnus Group cordially invites you to its “International Conference on Probiotics and Prebiotics” slated during June 15-16, 2022 at Rome, Italy. PROBIOTICS 2022 is scheduled in Hybrid Format with both onsite and virtual versions. We believe that our decision will enable broad participation.

The Mobile DNA Conference: Evolution, Diversity, and Impact

June 5-9, 2022 | Ireland

The first organized meeting that explicitly focused on mobile DNA and its impact on genomes took place in 1994. At the 2022 FASEB Science Research Conference (SRC) we will celebrate the notable progress in understanding transposon biology and evolution, their contribution to human diseases and normal physiological processes as well as in their wide-spread use as tools for basic science research and clinical applications.

Virtual Boston Paris Biotechnology Summit

September 29, 2022 | France

Funding in uncertain times, Legal Strategy, Talent Acquisition and Retention Three strategic points on your biotechnology company’s roadmap.

Cell and Gene Therapy Global Congress 2022

June 27-28, 2022 | UK

Cell and Gene therapies are life-changing new categories of medicines whose full potential is only just beginning to emerge. They are cutting-edge and rapidly progressing fields of Biological Therapies. Both therapies aim to treat, prevent or potentially cure diseases and both approaches offer the potential to diminish the fundamental cause of genetic and acquired diseases by substituting the missing protein or cells causing the disease’s symptoms. Cell and gene therapies may offer longer lasting effects than traditional medicines.

Spotlight

Mesenchymal stromal cells (MSCs) are prime candidates for regenerative medicine and therapeutic applications due to both their potent immuno-modulatory function and a unique ability to proliferate and differentiate into a variety of cell lineages. However, the stresses incurred during bio preservation /stability intervals (non-frozen and cryopreserved), including transit to and from the clinic can render MSCs ineffective and potentially unsafe. Challenges related to the formulation, transportation, distribution and delivery of source material (tissue, blood, marrow) and MSC-based products are important and inter-related components of the supply chain and scale-up. Effective bio preservation can optimize the quality of cell/tissue source material and final cell/tissue products, mitigate the adverse effects of interruptions and unforeseen events throughout the supply chain, as well as support the return to function of MSCs following patient administration.

resources